Chemesis International Inc.. Signs Definitive Agreement to Acquire of Puerto Rico According Natural Ventures PR LLC

Chemesis International Inc..

Signs Definitive Agreement to Acquire 80% of Puerto Rico According Natural Ventures PR LLC

Chemesis International Inc. (CSE: CSI), a market leader in medical and recreational cannabis, is pleased to announce that it has entered into a definitive agreement to acquire 80% of Natural Ventures PR LLC (“Natural Ventures”-RRB- through its subsidiary Chemesis PR, a 100 percent Puerto Rican company. The agreement amongst the parties has been submitted for approval as per required by its own regulatory framework to the Puerto Rico Medical Cannabis Board. Natural Ventures is a seed to sale cannabis firm based in Caguas, Puerto Rico, a United States Territory. Natural Ventures represents a substantial chance that will catapult Chemesis as a leader in both cannabis cultivation and medical and production.

Natural Ventures has been operational since early 2017 and is currently expanding to meet its growing patient demand. Natural Ventures is licensed to nurture 100,000 sq. ft. of cannabis and has 35,000 sq. ft. of manufacturing floor space for high quality cannabis products. It’s currently producing solvent and CO2 based extraction because of its oil-based goods, and it also is generating edibles and other cannabis products.

Puerto Rico legalized medical cannabis for qualifying health conditions in 2015 and allows the use of medical cannabis derivatives only (e.g., capsules, extractions, lotions, patches, edibles, flower, and oils). Currently, there are 18 pre-approved health conditions including cancer, HIV, multiple sclerosis, migraines, anxiety, and epilepsy which are eligible to be treated with cannabis. Chemesis is poised to meet demand as the island continues to expand the amount of qualifying conditions, and licenses are received by more patients.

“Natural Ventures’ acquisition is a really significant landmark for Chemesis,” said CEO of Chemesis Montero. “This acquisition gives the company revenue opportunities as well as access to a consumer base. The operations in Puerto Rico unlock the capacity to serve a large population for a variety of medical conditions, while having the ability to control costs and quality. The addition of Natural Ventures to the Chemesis family fits into our business model and growth strategy, because it will not only give a strong benefit to our revenue stream but will unlock other opportunities in the global market place that are vitally important,” said Montero.

In exchange for an 80% interest in the capital stock of Natural Ventures PR LLC, the corporation will pay US$2,250,000 cash and US$1,682,085 of stock valued at CAD$1.00 per common share, subject to a 36-month phased lock-up. Closing is subject to Puerto Rico Medical Cannabis Board approval that’s expected within 30 days. The business has agreed to create a convertible loan or capital contribution to Natural Ventures in the aggregate amount of US$750,000 on an as-needed foundation for expansion purposes.

About Chemesis International Inc..

Chemesis International Inc. is a vertically integrated global leader in the cannabis industry, with operations in California and exploring expansion through Latin America.

Chemesis is developing a strong foothold from farming. Chemesis has seed to sale operations, allowing for cost effective production and distribution of its products. Additionally, Chemesis leverages partnerships and exclusive brands and utilizes the highest quality extraction approaches to provide quality cannabis products to consumers.

While delivering quality products to its consumers from seed to 23, chemesis will add shareholder value.

Edgar Montero
CEO and Director

Forward-Looking Information: This news release contains”forward-looking information” within the meaning of applicable securities laws relating to statements regarding the Company’s business, products and future the Company’s business, its product offerings and strategies for sales and promotion. There can be no assurance that these expectations will prove to be right, Even though the Company believes that the expectations reflected in the forward-looking information are reasonable. Readers are cautioned not to place undue reliance on forward-looking info. Except as required by law, the Company expressly disclaims any obligation and does not intend, to update any forward-looking statements or information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that these expectations will prove to be right and makes no reference based on earnings reported. The statements in this news release are made as of the date of the release.

The CSE hasn’t reviewed, approved or disapproved the content of the press release

Primary Logo

Posted in: News

Comments are closed.